Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Description

Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

Conditions

Methamphetamine-dependence

Talk to us

Study Overview

On this page

Study Details

Study overview

Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Condition
Methamphetamine-dependence
Intervention / Treatment

-

Contacts and Locations

Portland

VA Portland Health Care System, Portland, OR, Portland, Oregon, United States, 97207-2964

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * abstinent from all drugs except marijuana and methamphetamine and have a negative urine drug screen on test days
  • * Meet diagnosis for recent Methamphetamine-Use Disorder (DSM-V) or does not meet any substance-use disorders
  • * Known sensitivity to ibudilast
  • * Left handed
  • * MRI contraindications
  • * Clinically significant neurological, endocrine, renal, hepatic, or systemic diseases that would compromise safe participation or confound outcomes
  • * Any psychiatric diagnoses or primary psychotic or mood disorders (past depression diagnoses allowed)
  • * Any drug use disorder diagnosis besides methamphetamine or tobacco
  • * Any recreational or prescriptive use of psychotropic medications
  • * Claustrophobia
  • * Women who are pregnant or breast-feeding
  • * Neurodegenerative diseases that present with neuroinflammation
  • * More than 4 weeks abstinent from methamphetamine
  • * rs6971 genotype that confers low translocator protein (TSPO) binding affinity to prevent unnecessary radiation exposure
  • * Liver disease requiring medication or medical treatment and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit
  • * Participation in any drug study in the last 3 months

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

VA Office of Research and Development,

Milky Kohno, PhD, PRINCIPAL_INVESTIGATOR, VA Portland Health Care System, Portland, OR

Study Record Dates

2025-12-31